NCT01745770View on ClinicalTrials.gov

TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)

PHASE3CompletedINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

June 30, 2015

Conditions
Active Ulcerative Colitis
Interventions
DRUG

Mesalazine - TID 1000 mg

DRUG

Mesalazine - TID 2x 500 mg

Trial Locations (1)

60431

Med. Klinik 1 - Markus-Krankenhaus, Frankfurt am Main

Sponsors
All Listed Sponsors
lead

Dr. Falk Pharma GmbH

INDUSTRY